RNS Number: 4142 M ABCAM PLC 16 September 2019 For immediate release. Cambridge, UK: Abcam plc, a global leader in the supply of life science research tools, was notified on 13 September 2019 that Gavin Wood, Chief Financial Officer, had purchased 2,500 Ordinary Shares of 0.2 pence each in the Company at an average price of £11.57 per share. RNS is approved by the...
RNS Number: 0389 M ABCAM PLC 12 September 2019 12 September 2019. Cambridge, UK: Abcam plc, will host a Capital Markets Event for institutional investors and analysts at its new global headquarters in Cambridge, UK on the afternoon of Thursday 14 November 2019.. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the...
RNS Number: 9720 L ABCAM PLC 11 September 2019 ABCAM PLC. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9694 L ABCAM PLC 11 September 2019 The following amendment has been made to the' Director/PDMR Shareholding' announcement released on 11 September 2019 at 7 am BST under RNS No 8901 L:. Cambridge, UK: Abcam plc, a global leader in the supply of life science research tools, was notified on 10 September 2019 that Alan Hirzel, Chief Executive Officer, had...
RNS Number: 8901 L ABCAM PLC 11 September 2019 For immediate release. Cambridge, UK: Abcam plc, a global leader in the supply of life science research tools, was notified on 10 September 2019 that Alan Hirzel, Chief Executive Officer, had purchased 4,350 Ordinary Shares of 0.2 pence each in the Company at an average price of £11.3895 per share. RNS is approved by the...
In line with its July trading update, full year results from Abcam (ABC) indicate a 9.2 per cent constant currency increase in revenue to £260m for FY2019 with adjusted cash profits rising by 4.6 per cent to £92.4m. Catalogue revenue has increased by 12 per cent to £243m whilst custom products and licensing revenue growth came in at 4.3 per cent to £17.1m. Statutory earnings have been weighed down by a £12.8m impairment charge on historic software development costs. Commencing a new five-year expansion plan, the adjusted cash profit margin is expected to decline from 35.6 per cent to 32-25 per cent next year as the group invests in growth. Shares are down over 11 per cent this morning.
Abcam Plc (ABC.L) Announced, in its full year results for the 12 months ended 30 June 2019, that its total revenue stood at £259.90 million, compared to £233.20 million in the preceding year. Profit after tax was £67.40 million compared to £66.70 million. The company’s diluted earnings per share was 32.60p, compared to 32.40p. The company declared an annual dividend of 12.13p per share, compared to 12.00p in the comparable period.
Long-term plan incorporates investment to achieve revenue of £450-500 m by FY24. Cambridge, UK: Abcam plc, a global leader in the supply of life science research tools, today announces its preliminary results for the 12 months ended 30 June 2019.. ·Operating profit margin of 21.6%, after a £12.8 m non-cash impairment charge relating to historic Enterprise...
RNS Number: 9445 K ABCAM PLC 02 September 2019 ABCAM PLC. Total Voting Rights- Voting Rights and Capital. In conformity with the Disclosure Rules and Transparency Rules, provision 5.6. 1, the Company notifies the market of the following: The Company's issued share capital consists of 205,736,276 Ordinary Shares of 0.2 p each with voting rights.
RNS Number: 5936 H ABCAM PLC 01 August 2019 ABCAM PLC. Total Voting Rights- Voting Rights and Capital. In conformity with the Disclosure Rules and Transparency Rules, provision 5.6. 1, the Company notifies the market of the following: The Company's issued share capital consists of 205,722,049 Ordinary Shares of 0.2 p each with voting rights.
Life sciences research tools supplier Abcam has issued a trading statement saying that it expects full-year revenues to increase by 11.4% to £260m. The company says it will set out a new five-year plan at its results in September. Separately, chief financial officer Gavin Wood, has served notice of his intention to step down over the next year in order to “continue his career closer to his family home”.
ABCAM Plc (ABC.L) Announced, in its trading update, that overall, the group expects to report total revenue of £259.9 million (2017/18: £233.2 million), representing growth for the year of 11.4% on a reported basis and 9.2% on a constant currency basis. The Group expects gross margin to be ahead of last year and Adjusted EBITDA margin to be in line with the Board's expectations. The Board is currently reviewing its plans for the next five years to 2023/24 and sees significant opportunity to further grow the organisation organically through a programme of internally funded investments. The Group will report its full year results for the twelve-month period ended 30 June 2019 on 9 September 2019. Separately, the company announced that its Chief Financial Officer, Gavin Wood, has today served notice of his intention to step down from the Board over the next year in order to continue his career closer to his family home. The search for his successor will commence immediately and Gavin is committed to delivering an orderly transition over the coming months.
RNS Number: 1978 G ABCAM PLC 22 July 2019 22 July 2019. Abcam plc, a global leader in the supply of life science research tools, announces that its Chief Financial Officer, Gavin Wood, has today served notice of his intention to step down from the Board over the next year in order to continue his career closer to his family home. The search for his successor will commence...
RNS Number: 1977 G ABCAM PLC 22 July 2019 22 July 2019. Overall, the Group expects to report total revenue of £259.9 million, representing growth for the year of 11.4% on a reported basis and 9.2% on a constant currency basis.. Revenue in China grew faster than market at over 20% in the year and represents over 15% of total company sales..
ABCAM PLC (ABC) 1,361p £2,799m Abcam, a global innovator in life science reagents and tools, announced the acquisition of the entire live cell line and lysates portfolio of EdiGene Inc, a leading company focused on developing genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery. Using their proprietary high-throughput cell editing platform, EdiGene developed the industry's largest off-the shelf diploid library of over 2,800 single clonal knockout (KO) cell lines targeting over 2,600 genes in commonly used human cancer cell lines (including HeLa, HEK293-T, A549, HCT116, Hep G2 and MCF7). Ready-made diploid KO cell lines are an important tool for antibody validation. They also play a significant role in the study and understanding of biological pathways and disease models and can be used in screening and cellular assays. EdiGene's cell lines and lysates are used by top academic researchers, global biopharmaceutical companies, and leading antibody companies. Financial terms of the transaction have not been disclosed and are expected to have a minimal impact on revenue and earnings in the current financial year.
Abcam Plc (ABC.L) Announced the acquisition of the entire live cell line and lysates portfolio of EdiGene Inc, a leading company focused on developing genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery. Financial terms of the transaction have not been disclosed and are expected to have a minimal impact on revenue and earnings in the current financial year.
RNS Number: 6031 F ABCAM PLC 16 July 2019. Abcam Enters Cell Editing Market Through. Acquisition of EdiGene's Knock-out Cell Lines and Lysates Portfolio.
RNS Number: 6031 F ABCAM PLC 16 July 2019. Abcam Enters Cell Editing Market Through. Acquisition of EdiGene's Knock-out Cell Lines and Lysates Portfolio.
RNS Number: 0010 E ABCAM PLC 01 July 2019 ABCAM PLC. Total Voting Rights- Voting Rights and Capital. In conformity with the Disclosure Rules and Transparency Rules, provision 5.6. 1, the Company notifies the market of the following: The Company's issued share capital consists of 205,671,564 Ordinary Shares of 0.2 p each with voting rights.
RNS Number: 9356 A ABCAM PLC 03 June 2019 ABCAM PLC. Total Voting Rights- Voting Rights and Capital. In conformity with the Disclosure Rules and Transparency Rules, provision 5.6. 1, the Company notifies the market of the following: The Company's issued share capital consists of 205,627,534 Ordinary Shares of 0.2 p each with voting rights.
Abcam Plc
ABC.L
Abcam Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    205.49M

Company Profile

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in understanding health and disease.

Classification

Market Indices-

Locations

HQ
330 Cambridge Science Park
Milton Road
Cambridge
CB4 0FL
Watchlist